Brief: Ascentage Pharma Group International Gets FDA Clearance To Start Phase 3 Clinical Trial For Olverembatinib
14/02/2024 01:31
Feb 14 (Reuters) - Ascentage Pharma Group International
6855.HK :
* GOT CLEARANCE FROM U.S. FDA TO INITIATE GLOBAL
REGISTRATIONAL
PHASE 3 CLINICAL TRIAL FOR OLVEREMBATINIB
Source text for Eikon: ID:n11068605-1
Further company coverage: 6855.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ascentage Pharma International
See all newsBrief: Ascentage Pharma Group Says Lisaftoclax Granted Breakthrough Therapy Designation In China
China's Ascentage Pharma climbs as chairman buys shares on market
Brief: Ascentage Pharma Group International's Chairman Buys 38,630 Shares
Brief: Ascentage Pharma Group International Posts H1 Net Loss Attributable RMB816.7 Million
China's Ascentage Pharma H1 revenue rises 29% on Lisaftoclax ramp-up